Oral
T-DXd
JBCS 2025 | July 10-12, 2025
Breast Cancer
AI-based analyses of trastuzumab deruxtecan-related interstitial lung disease/pneumonitis: TILD-A
Naoya Tanabe
Oral
T-DXd
JBCS 2025 | July 10-12, 2025
Breast Cancer
HER2-low and HER2-ultralow status determination in HR+ metastatic breast cancer: DESTINY-Breast06
Junji Tsurutani
Oral
T-DXd
JBCS 2025 | July 10-12, 2025
Breast Cancer
The effectiveness of post-T-DXd treatments in HER2+ metastatic BC patients: The EN-SEMBLE Study
Toru Mukohara
Oral
T-DXd, Valemetostat
JBCS 2025 | July 10-12, 2025
Breast Cancer
Valemetostat and T-DXd for HER2-low, previously treated, unresectable or metastatic breast cancer
Yoichi Naito